Home/Filings/4/0000905718-17-000668
4//SEC Filing

DelMar Pharmaceuticals, Inc. 4

Accession 0000905718-17-000668

$HURACIK 0001498382operating

Filed

Jul 10, 8:00 PM ET

Accepted

Jul 11, 9:41 PM ET

Size

7.8 KB

Accession

0000905718-17-000668

Insider Transaction Report

Form 4
Period: 2017-07-07
Zarrabian Saiid
DirectorInterim CEO
Transactions
  • Award

    Options (Right to Buy)

    2017-07-07+36,00036,000 total
    Exercise: $2.11From: 2020-07-07Exp: 2027-07-07Common Stock (36,000 underlying)
  • Award

    Performance Stock Units

    2017-07-07+200,000200,000 total
    Exp: 2022-07-07Common Stock (200,000 underlying)
Footnotes (2)
  • [F1]12,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018.
  • [F2]Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on targets related to the Company's financial performance.

Issuer

DelMar Pharmaceuticals, Inc.

CIK 0001498382

Entity typeoperating
IncorporatedNV

Related Parties

1
  • filerCIK 0001498382

Filing Metadata

Form type
4
Filed
Jul 10, 8:00 PM ET
Accepted
Jul 11, 9:41 PM ET
Size
7.8 KB